- Trials with a EudraCT protocol (899)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
899 result(s) found for: AST ALT ratio.
Displaying page 1 of 45.
EudraCT Number: 2016-001038-91 | Sponsor Protocol Number: NL57115 | Start Date*: 2016-11-18 |
Sponsor Name:Leiden university medical centre | ||
Full Title: A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis | ||
Medical condition: Autoimmune hepatitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001107-27 | Sponsor Protocol Number: SI0207 | Start Date*: 2010-05-07 |
Sponsor Name:Universität Leipzig | ||
Full Title: PHASE I-II MULTICENTER STUDY OF P210-B2A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TR... | ||
Medical condition: Chronic myeloid leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004645-36 | Sponsor Protocol Number: TMP-2501-2019-2 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) | |||||||||||||
Full Title: Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER) | |||||||||||||
Medical condition: Drug-induced elevated liver enzymes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000819-25 | Sponsor Protocol Number: DS102A-05-AH1 | Start Date*: 2019-01-31 | |||||||||||
Sponsor Name:Afimmune | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis. | |||||||||||||
Medical condition: Severe Acute Decompensated Alcoholic Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000095-42 | Sponsor Protocol Number: 1199.52 | Start Date*: 2014-10-08 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm.V | |||||||||||||
Full Title: A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therap... | |||||||||||||
Medical condition: Patients with metastatic colorectal cancer refractory to standards therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LU (Completed) IT (Completed) SE (Completed) AT (Completed) DK (Completed) BE (Completed) DE (Completed) PT (Completed) NL (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003119-22 | Sponsor Protocol Number: EYP001-202 | Start Date*: 2019-05-20 | |||||||||||
Sponsor Name:ENYO Pharma SA | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis | |||||||||||||
Medical condition: Nonalcoholic steatohepatitis with likely stage F2 to F3 fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004008-71 | Sponsor Protocol Number: ELDORADO | Start Date*: 2017-01-19 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’ | ||
Medical condition: Estrogen receptor positive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001541-39 | Sponsor Protocol Number: BEVACOR | Start Date*: 2020-04-24 | ||||||||||||||||
Sponsor Name:Fundación para la Investigación Biomédica de Córdoba | ||||||||||||||||||
Full Title: Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
Medical condition: Acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005215-33 | Sponsor Protocol Number: CLJN452A2202 | Start Date*: 2016-06-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, 3- part, adaptive design, multicenter study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with non-alcoholic steatoh... | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004605-38 | Sponsor Protocol Number: NUC-4/NAS | Start Date*: 2015-02-11 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver di... | |||||||||||||
Medical condition: Non-alcoholic fatty liver disease (NAFLD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002984-24 | Sponsor Protocol Number: PHS-Px-104-II-01 | Start Date*: 2013-10-07 | |||||||||||
Sponsor Name:Phenex Pharmaceuticals AG | |||||||||||||
Full Title: A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients | |||||||||||||
Medical condition: Non-alcoholic fatty liver disease (NAFLD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004365-27 | Sponsor Protocol Number: EDP-305-101 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:Enanta Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-Alcoholic Steatohep... | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001762-13 | Sponsor Protocol Number: 747-401 | Start Date*: 2018-08-01 |
Sponsor Name:Intercept Pharmaceuticals, Inc. | ||
Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa... | ||
Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-004319-29 | Sponsor Protocol Number: 20120283 | Start Date*: 2013-05-03 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer | |||||||||||||
Medical condition: HER2 Positive Early Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) HU (Completed) SK (Completed) IT (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000849-23 | Sponsor Protocol Number: HC-G-H-1403 | Start Date*: 2017-08-21 | |||||||||||
Sponsor Name:B. Braun Melsungen AG | |||||||||||||
Full Title: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSION | |||||||||||||
Medical condition: Chronic intestinal failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001586-27 | Sponsor Protocol Number: SOMCT01-C | Start Date*: 2014-07-25 | |||||||||||
Sponsor Name:SOM Innovation Biotech SL (SOM Biotech) | |||||||||||||
Full Title: Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity | |||||||||||||
Medical condition: Patients with familial amyloid polyneuropathy (FAP), asymptomatic carriers and healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005002-40 | Sponsor Protocol Number: 0653A-134 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: "Estudio aleatorizado, doble ciego, con control activo, multicéntrico en pacientes con hipercolesterolemia primaria y alto riesgo cardiovascular y no controlados adecuadamente con Atorvastatina 20 ... | |||||||||||||
Medical condition: hipercolesterolemia primaria primary hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Completed) PT (Completed) LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005708-18 | Sponsor Protocol Number: 14081962 | Start Date*: 2010-06-04 |
Sponsor Name:Queen Mary University of London | ||
Full Title: Prevention of metabolic complications of glucocorticoid excess | ||
Medical condition: Rheumatoid arthritis, SLE, Polymyalgia rheumatica, Disthyroid eye disease, Cushing's syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004604-29 | Sponsor Protocol Number: 210710120713 | Start Date*: 2015-04-27 | |||||||||||
Sponsor Name:Jens Rolighed Larsen | |||||||||||||
Full Title: Sevoflurane versus standard general anesthesia in elective open abdominal aortic aneurism surgery | |||||||||||||
Medical condition: Abdominal aortic aneurism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006161-13 | Sponsor Protocol Number: ML19983 | Start Date*: 2007-06-22 |
Sponsor Name:Roche Pharma AG | ||
Full Title: A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with meta... | ||
Medical condition: Metastatic renal cell cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
